Yvonne Katterle
Wuppertal, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Use of surrogate matrices in bioanalytical preclinical safety testing using immunoassay methods: a recommendation from the European Bioanalysis Forum.
Journal: Bioanalysis
Published: August 09, 2025
Recent discussions and proposals on challenging the 3-tier immunogenicity testing strategies from the European bioanalysis forum.
Journal: Bioanalysis
Published: April 09, 2025
The effectiveness of quality control samples in pharmaceutical bioanalysis.
Journal: Bioanalysis
Published: February 04, 2021
Factor VIII activity of BAY 94-9027 is accurately measured with most commonly used assays: Results from an international laboratory study.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: June 04, 2018
Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.
Journal: Clinical pharmacokinetics
Published: December 23, 2016
BAY 81-8973, a full-length recombinant factor VIII: Human heat shock protein 70 improves the manufacturing process without affecting clinical safety.
Journal: Protein expression and purification
Published: May 04, 2016
BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field study.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: January 21, 2016
Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samples.
Journal: Journal of thrombosis and haemostasis : JTH
Published: October 09, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026